西非HIV-1亚型在整合酶抑制剂治疗前高携L74I突变
本研究对115例未接受整合酶抑制剂治疗的尼日利亚患者(59.1%为CRF02_AG,40.9%为G亚型)进行整合酶耐药突变检测,发现40%携带L74I突变,且G亚型中更常见,主要整合酶耐药突变罕见。
要点
- 西非HIV-1感染者中L74I突变预存率高(40%),尤其G亚型(55.3%)
- 主要整合酶耐药突变罕见,仅4例低水平检出
- L74I与整合酶抑制剂治疗失败相关,需关注非B亚型疗效
核心结论
- 西非流行的HIV-1亚型中主要整合酶突变流行率很低,但L74I突变流行率显著。
研究设计与样本
- 研究纳入115例接受二线PI方案且未用过整合酶抑制剂的尼日利亚患者,采用Illumina二代测序检测存储血浆样本。
主要发现
- L74I在40%(46/115)的血浆样本中以超过2%频率检出。
- G亚型感染者的L74I流行率(55.3%,26/47)高于CRF02_AG感染者(29.4%,20/68),P=0.005。
- 4例检出主要整合酶耐药突变(2例Q148K弱势变异,2例R263K,其中1例合并L74I),频率为2%-5%。
关键数值与推荐
- 耐药判读使用斯坦福耐药数据库和IAS-USA 2019突变列表。
- L74I检出定义为频率超过2%,弱势变异定义为2%-20%。
- 主要整合酶耐药突变指IAS-USA列表中的突变。
临床怎么用
- 在非B亚型(尤其G亚型)HIV感染者中使用整合酶抑制剂前,应了解L74I预存情况及其对疗效的潜在影响。
- 对治疗失败者需结合耐药检测谨慎解读L74I等弱势变异。
局限性
- 样本来自尼日利亚单国队列,结论外推至西非其他地区需谨慎。
- 原文未报告L74I与临床治疗失败的直接关联数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though efficacy and resistance data for non-B subtypes are limited. Two recent trials have identified the integrase L74I mutation to be associated with integrase inhibitor treatment failure in HIV-1 non-B subtypes. We sought to define the prevalence of integrase resistance mutations, including L74I, in West Africa. METHODS: We studied a Nigerian cohort of recipients prior to and during receipt of second-line PI-based therapy, who were integrase inhibitor-naive. Illumina next-generation sequencing with target enrichment was used on stored plasma samples. Drug resistance was interpreted using the Stanford Resistance Database and the IAS-USA 2019 mutation lists. RESULTS: Of 115 individuals, 59.1% harboured CRF02_AG HIV-1 and 40.9% harboured subtype G HIV-1. Four participants had major IAS-USA integrase resistance-associated mutations detected at low levels (2%-5% frequency). Two had Q148K minority variants and two had R263K (one of whom also had L74I). L74I was detected in plasma samples at over 2% frequency in 40% (46/115). Twelve (26.1%) had low-level minority variants of between 2% and 20% of the viral population sampled. The remaining 34 (73.9%) had L74I present at >20% frequency. L74I was more common among those with subtype G infection (55.3%, 26/47) than those with CRF02_AG infection (29.4%, 20/68) (P = 0.005). CONCLUSIONS: HIV-1 subtypes circulating in West Africa appear to have very low prevalence of major integrase mutations, but significant prevalence of L74I. A combination of in vitro and clinical studies is warranted to understand the potential implications.
引用
- El Bouzidi K, Kemp SA, Datir RP, et al. High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment. J Antimicrob Chemother. 2020. PMID: 32105319. doi:10.1093/jac/dkaa033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。